Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temsirolimus - Pfizer

Next Previous
Drug Profile

Temsirolimus - Pfizer

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; National Comprehensive Cancer Network; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma; Thyroid cancer
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Australia (IV, Infusion)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Canada (IV, Infusion)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top